Form 13-F position report

REVOLUTION MEDICINES INC

Reported by Paradigm Biocapital Advisors LP

RVMD CUSIP 76155X100 Manager CIK 0001855655

Reported 6,219,323 shares, down 142,000 (2.2%) from the prior quarter.

Reported value 7.2%; share count -2.2% vs. the prior quarter.

Reduced
% of reported 13F value 25.38% This manager · Q3 2026
Shares 6,219,323 Quarter-end amount reported
Reported value $1,276,578,239 Fair value at quarter end
Consecutive quarters held 11 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-03-31 93949644
2024-06-30 204105244
2024-09-30 240993936
2024-12-31 286633075
2025-03-31 218458005
2025-06-30 224172176
2025-09-30 290627690
2025-12-31 529226699
2026-03-31 647267117
2026-06-30 1191348571
2026-09-30 1276578239

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for REVOLUTION MEDICINES INC held by Paradigm Biocapital Advisors LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 6,219,323 -142,000 (-2.2%) 25.38% $1,276,578,239 2026-11-16
Q2 2026 Reduced 6,361,323 -294,380 (-4.4%) 22.31% $1,191,348,571 2026-08-14
Q1 2026 Added 6,655,703 +11,300 (0.2%) 13.23% $647,267,117 2026-05-15
Q4 2025 Added 6,644,403 +421,112 (6.8%) 13.51% $529,226,699 2026-02-17
Q3 2025 Added 6,223,291 +130,000 (2.1%) 8.27% $290,627,690 2025-11-14
Q2 2025 Reduced 6,093,291 -84,820 (-1.4%) 9.57% $224,172,176 2025-08-14
Q1 2025 Reduced 6,178,111 -375,000 (-5.7%) 10.01% $218,458,005 2025-05-15
Q4 2024 Added 6,553,111 +1,239,022 (23.3%) 9.97% $286,633,075 2025-02-14
Q3 2024 Added 5,314,089 +55,000 (1.0%) 8.15% $240,993,936 2024-11-14
Q2 2024 Added 5,259,089 +2,344,114 (80.4%) 7.81% $204,105,244 2024-08-14
Q1 2024 New 2,914,975 +2,914,975 (0.0%) 3.31% $93,949,644 2024-05-15

Who else reported the position

825 managers reported REVOLUTION MEDICINES INC for Q3 2026.

Managers reporting REVOLUTION MEDICINES INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 15,397,714 +3,197,292 0.14% $3,160,534,467 27 qtrs
BlackRock Inc Added 13,857,324 +161,534 0.04% $2,844,354,468 9 qtrs
FARALLON CAPITAL MANAGEMENT LLC Reduced 13,418,796 -132,000 11.87% $2,754,342,067 23 qtrs
BAKER BROS ADVISORS LP Reduced 10,637,318 -806,039 10.38% $2,183,415,893 23 qtrs
Darwin Global Management Ltd Unchanged 10,629,822 0 54.66% $2,181,877,264 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 9,149,534 +60,873 0.04% $1,878,033,349 3 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 8,157,073 -137,782 0.08% $1,674,320,804 3 qtrs
Nextech Invest Ltd Unchanged 7,601,087 0 69.89% $1,560,199,118 7 qtrs
JANUS HENDERSON GROUP PLC Reduced 7,573,603 -2,192,893 0.66% $1,555,023,854 1 qtr
Paradigm Biocapital Advisors LP This report Reduced 6,219,323 -142,000 25.38% $1,276,578,239 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
6,219,323
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.